Impact of Hyperemic State on Angio-IMR Performance
The Impact of Hyperemic State on the Performance of Angiography Derived Indices in Assessing Coronary Microvascular Disease
The goal of this observational study is to evaluate the diagnostic performance of angiography-derived microcirculatory indices (Angio-IMR) in assessing patients with stable angina or suspected coronary artery disease. The main questions it aims to answer are:
How do the numerical values of Angio-IMR from five different software vendors change across three physiological states (resting, sub-hyperemia induced by nitroglycerin, and maximal hyperemia induced by adenosine)? Which physiological state and software algorithm provide the highest diagnostic accuracy (Area Under the Curve, AUC) for diagnosing Coronary Microvascular Disease (CMD) when compared to the gold standard wire-based IMR? Researchers will compare the Angio-IMR results calculated under the three different physiological conditions within the same patient to see how the hyperemic state impacts the performance and consistency of these non-invasive indices.
Participants will:
Undergo standard-of-care coronary angiography and physiological assessment using a pressure wire for index of microvascular resistance (Wire-IMR) as part of their clinical management.
Have their angiographic images captured at three specific time points: at rest, after intracoronary nitroglycerin, and during adenosine-induced maximal hyperemia.
Allow their de-identified imaging and clinical data to be analyzed by an independent core laboratory using five different Angio-IMR software platforms to evaluate microvascular function.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Study Overview and Procedural Protocol
This is a prospective, multi-center, diagnostic accuracy study employing a self-controlled design. All participants will undergo coronary angiography and physiological assessment according to standard clinical indications. During the procedure, specific angiographic images will be systematically captured for the target vessel at three distinct physiological time points:
Resting State: Baseline coronary angiography without any hyperemic agents. Sub-hyperemic State: Following the intracoronary administration of nitroglycerin.
Maximal Hyperemic State: During continuous intracoronary infusion of adenosine to achieve maximal microvascular vasodilation.
Immediately following image acquisition, the reference standard measurement-Wire-IMR-will be performed using a pressure-sensor-equipped guidewire under maximal hyperemia.
Core Laboratory Imaging Analysis and Blinding
All angiographic data will be de-identified and transferred to a centralized, independent Cardiovascular Imaging Core Laboratory at Zhongshan Hospital, Fudan University. The analysis will be conducted as follows:
Software Platforms: Five different commercially available Angio-IMR software platforms (anonymized as A, B, C, D, and E) will be used to calculate microvascular resistance.
Independent Analysis: Five dedicated analysts, each specialized in one specific software platform, will perform the calculations. Each analyst will be blinded to the patients' clinical information, the Wire-IMR gold standard results, and the results from the other four software platforms.
Standardization: A primary researcher, not involved in the software measurements, will pre-define the target vessel segments and measurement frames to ensure consistency across all five software platforms.
Statistical Considerations and Data Management The study aims to determine if the coronary hyperemic state significantly alters the fluid dynamics modeling utilized by Angio-IMR algorithms. AUC will be calculated for each software at each of the three states. A head-to-head comparison of AUCs will be performed using DeLong's test. To maintain data integrity, results from the core laboratory and the clinical centers will remain strictly separated until the final database lock.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Jinying Zhou, MD, PhD
- E-Mail: zhou.jinying@zs-hospital.sh.cn
Studieren Sie die Kontaktsicherung
- Name: Chenguang Li, MD, PhD
- Telefonnummer: 021 6404 1990
- E-Mail: li.chenguang@zs-hospital.sh.cn
Studienorte
-
-
-
Guangzhou, China
- Rekrutierung
- The First Affiliated Hospital, Sun Yat-sen University
-
Kontakt:
- Xun Hu, MD, PhD
- Telefonnummer: 020-87608185
- E-Mail: hxun@mail.sysu.edu.cn
-
-
Please Select
-
Shanghai, Please Select, China, 200000
- Rekrutierung
- Zhongshan Hospital, Fudan University
-
Kontakt:
- Jinying Zhou, MD, PhD
- Telefonnummer: 021 6404 1990
- E-Mail: zhou.jinying@zs-hospital.sh.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
The study population consists of adult patients (aged 18 and older) clinically diagnosed with stable angina or suspected coronary artery disease who are scheduled to undergo conventional coronary angiography and invasive physiological assessment.
Participants are prospectively and consecutively recruited from multiple clinical centers in China. The population specifically targets individuals with non-obstructive coronary arteries (stenosis < 50%) or those with moderate stenosis (50%-90%) but preserved epicardial flow (FFR > 0.80), where assessment of coronary microvascular function is clinically indicated to investigate the cause of ischemia.
Beschreibung
Inclusion Criteria:
- Stable angina or suspected coronary heart disease.
- Scheduled for coronary angiography and physiological assessment.
- Target vessel with stenosis < 50% or 50%-90% with fractional flow reserve (FFR) > 0.80.
- Provided informed consent.
Exclusion Criteria:
- Hemodynamic instability (acute myocardial infarction, cardiogenic shock, severe arrhythmia).
- Contraindications to angiography (e.g., end-stage renal disease).
- Contraindications to adenosine (e.g., severe asthma, high-degree atrial-ventricular block).
- Life expectancy < 1 year or pregnancy.
- Target vessel unsuitable for wire operation (left main lesion, severe tortuosity) or stenosis > 90%.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Single cohort, self-controlled
|
Unlike the reference standard "Wire-IMR," which requires the advancement of a specialized pressure-sensor guidewire into the distal coronary artery, Angio-IMR is a wire-free technology.
It derives microvascular resistance indices purely through computational fluid dynamics (CFD) or specialized mathematical models based on standard coronary angiographic projections.
This eliminates the risk of wire-induced vascular injury or spasm.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Area Under the ROC Curve (AUC)
Zeitfenster: Baseline
|
Comparison of AUC for 5 types of Angio-IMR against Wire-IMR (Gold standard, CMD defined as Wire-IMR ≥ 25) under three states.
|
Baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diagnostic Accuracy
Zeitfenster: Baseline
|
Sensitivity, specificity, positive predictive value, negative predictive value.
|
Baseline
|
|
Correlation
Zeitfenster: Baseline
|
Pearson/Spearman coefficients between Angio-IMR and Wire-IMR.
|
Baseline
|
|
Agreement
Zeitfenster: Baseline
|
Bland-Altman analysis (Bias and Limits of Agreement).
|
Baseline
|
|
Inter-vendor Agreement
Zeitfenster: Baseline
|
Consistency between different software brands.
|
Baseline
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- B2026-265
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Koronare Herzkrankheit
-
Zhejiang Cancer HospitalRekrutierungHepatic Artery Infusion | Lebermetastasen bei BrustkrebsChina
-
National Medical Research Center for Therapy and...Stupino Clinical Hospital, Moscow Region State Medical InstitutionAbgeschlossenUNTERSCHALTE CORONARY SYNDROMERussland
-
Medical University of WarsawRekrutierungANOCA | Angina ohne obstruktive Koronararterienerkrankung | Coronary Sinus ReduderPolen
Klinische Studien zur Angiography-derived IMR
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.ZurückgezogenHerzinsuffizienz mit erhaltener Ejektionsfraktion
-
University Hospital, AkershusBeendetBipolare Störung | Psychose | Andere Diagnosen und ZuständeNorwegen
-
Consorzio Futuro in RicercaAbgeschlossenRefraktäre Angina pectorisItalien
-
University of WashingtonAbgeschlossenSchizophrenie | Bipolare Störung | Schwere psychische Erkrankung
-
Imara, Inc.Aktiv, nicht rekrutierendSichelzellenanämieVereinigte Staaten, Vereinigtes Königreich
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.Beendetβ-ThalassämieIsrael, Frankreich, Malaysia, Truthahn, Dänemark, Georgia, Griechenland, Italien, Libanon, Marokko, Niederlande, Tunesien, Vereinigtes Königreich
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.BeendetSichelzellenanämieVereinigte Staaten, Oman, Italien, Vereinigtes Königreich, Libanon, Griechenland, Marokko, Tunesien, Ghana, Kenia, Niederlande, Senegal, Uganda
-
Cardurion Pharmaceuticals, Inc.Imara, Inc.AbgeschlossenSichelzellenanämieVereinigte Staaten, Vereinigtes Königreich
-
University Hospital, AkershusHelse Sor-Ost; RomeriksprosjektetAbgeschlossenPsychische Störungen | Stimmungsschwankungen | Schizophrenie | Bipolare Störung | Affektive Störungen, PsychotischeNorwegen
-
Capricor Inc.National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... und andere MitarbeiterUnbekanntHerzfehler | Ischämische Kardiomyopathie | Nichtischämische Kardiomyopathie | Dilatative Kardiomyopathie (DCM)Vereinigte Staaten